NCT06186804 - A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

October 30, 2026

Study Completion Date

December 30, 2026

Conditions

cGvHD

Interventions

DRUG

ABSK021

Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.

Trial Locations (14)

215000

The First affiliated hospital of SuZhou University, Suzhou

Unknown

Peking University People's Hospital, Beijing

The Second Affiliated Hospital of the Army Medical University, Chongqing

Fujian Medical University Union Hospital, Fuzhou

Guangdong Provincial Peoplep's Hospital, Guangzhou

ZhuJiang Hospital of Southern Medical University, Zhujiang

Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan

Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan

The Fir St Affiliated Hospital,Zhejiang Univer Sity School of Medicine, Hangzhou

The First Affiliated Hospital of Nanchang University, Nanchang

The First Hospital of Jilin University, Changchun

West China Hospital of Sichuan University, Chengdu

Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin

The First Teaching Hospital of Xinjiang Medical University, Xinjiang